[Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma]

K M Abdulkadyrov; L V Stel'mashenko; S S Bessmel'tsev; I F Lubo-Lesnichenko; A V Sel'tser; O E Rozanova; N K Gubarenko; L N Bubnova; M M Mnuskina; A A Zhuchikhina; M N Blinov; N L Gritskevich

[Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma]

Vopr Onkol. 1998;44(3):304-9.

[Article in Russian]

Authors

K M Abdulkadyrov¹, L V Stel'mashenko, S S Bessmel'tsev, I F Lubo-Lesnichenko, A V Sel'tser, O E Rozanova, N K Gubarenko, L N Bubnova, M M Mnuskina, A A Zhuchikhina, M N Blinov, N L Gritskevich

Affiliation

¹ Russian Research Institute of Hematology and Transfusiology, Municipal Diagnostic Center, St.Petersburg.

PMID: 9695777

Abstract

The results of examination of 58 patients in the course of multiple myeloma (MM) are discussed. Prognosis for LDH, beta2-m and FNO-alpha administration was evaluated versus immunochemical pattern, tumor mass and response to different chemotherapeutic regimens. High prognostic value of serum levels of LDH, beta2 and FNO-alpha in MM patients was observed. The method may be useful in carrying out chemotherapy and detecting recurrences and chemoresistance.

Publication types

English Abstract

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor / blood*
Female
Humans
L-Lactate Dehydrogenase / blood
Male
Middle Aged
Multiple Myeloma / blood*
Multiple Myeloma / drug therapy
Multiple Myeloma / immunology*
Predictive Value of Tests
Prognosis
beta 2-Microglobulin / metabolism

Substances

Biomarkers, Tumor
beta 2-Microglobulin
L-Lactate Dehydrogenase